Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rayne H Rouce

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Blood|December 25, 2023
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasLaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, et al.
Blood Advances|June 24, 2025
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registrySamuel John, Kevin J Curran, Erin M Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Cancers|December 5, 2020
Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin LymphomaJennifer E Agrusa, Brooks P Scull, Harshal A Abhyankar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T CellsNatalia Lapteva, Margaret Gilbert, Iulia Diaconu, et al.
Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Haematologica|October 20, 2022
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemiaAlan S Wayne, Van Huynh, Nobuko Hijiya, et al.
Blood|December 25, 2023
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomasLaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, et al.
Blood Advances|June 24, 2025
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registrySamuel John, Kevin J Curran, Erin M Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical EffectsSpyridoula Vasileiou, Premal D Lulla, Ifigeneia Tzannou, et al.
Blood|March 24, 2022
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECsDavid H M Steffin, Ibrahim N Muhsen, LaQuisa C Hill, et al.
Cancers|December 5, 2020
Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin LymphomaJennifer E Agrusa, Brooks P Scull, Harshal A Abhyankar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2019
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T CellsNatalia Lapteva, Margaret Gilbert, Iulia Diaconu, et al.
Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.
Pageof 6